{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T04:38:02Z","timestamp":1648874282149},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Frankfurt"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To evaluate the impact of testing asymptomatic cancer patients, we analyzed all tests for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) before and during radiotherapy at a\u00a0tertiary cancer center throughout the second wave of the pandemic in Germany.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Results of all real-time polymerase chain reaction (RT-PCR) tests for SARS-CoV\u20112 performed at our radio-oncology department between 13\u00a0October 2020 and 11\u00a0March 2021 were included. Clinical data and anamnestic information at the time of testing were documented and examined for (i)\u00a0the presence of COVID-19-related symptoms and (ii)\u00a0virus-related anamnesis (high-risk [prior positive test or contact to a\u00a0positive tested person within the last 14\u00a0days] or low-risk [inconspicuous anamnesis within the last 14\u00a0days]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1056 SARS-CoV\u20112 tests in 543\u00a0patients were analyzed. Of those, 1015 tests were performed in asymptomatic patients and 41\u00a0tests in patients with COVID-19-associated symptoms. Two of 940 (0.2%) tests in asymptomatic patients with low-risk anamnesis and three of 75 (4.0%) tests in asymptomatic patients with high-risk anamnesis showed a\u00a0positive result. For symptomatic patients, SARS-CoV\u20112 was detected in three of 36 (8.3%) low-risk and three of five (60.0%) high-risk tests.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>To the best of our knowledge, this is the first study evaluating the correlation between individual risk factors and positivity rates of SARS-CoV\u20112 tests in cancer patients. The data demonstrate that clinical and anamnestic assessment is a\u00a0simple and effective measure to distinctly increase SARS-CoV\u20112 test efficiency. This might enable cancer centers to adjust test strategies in asymptomatic patients, especially when test resources are scarce.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00066-021-01853-7","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T05:16:11Z","timestamp":1633583771000},"page":"354-360","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk stratification by anamnesis increases SARS-CoV-2 test efficiency in cancer patients"],"prefix":"10.1007","volume":"198","author":[{"given":"Christian Cornelius","family":"Arnold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"von\u00a0der\u00a0Gr\u00fcn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark Christoph","family":"Brekner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Licher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouil","family":"Fokas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"R\u00f6del","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"key":"1853_CR1","unstructured":"Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) COVID-19 dashboard. https:\/\/coronavirus.jhu.edu\/map.html. Accessed 23 May 2021"},{"key":"1853_CR2","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1158\/2159-8290.CD-20-0773","volume":"10","author":"DJ Pinato","year":"2020","unstructured":"Pinato\u00a0DJ, Zambelli\u00a0A, Aguilar-Company\u00a0J et al (2020) Clinical portrait of the SARS-CoV\u20112 epidemic in European cancer patients. Cancer Discov 10:1465\u20131474. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0773","journal-title":"Cancer Discov"},{"key":"1853_CR3","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S1470-2045(20)30442-3","volume":"21","author":"LYW Lee","year":"2020","unstructured":"Lee\u00a0LYW, Cazier\u00a0J\u2011B, Starkey\u00a0T et al (2020) COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a\u00a0prospective cohort study. Lancet Oncol 21:1309\u20131316. https:\/\/doi.org\/10.1016\/S1470-2045(20)30442-3","journal-title":"Lancet Oncol"},{"key":"1853_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ejca.2021.01.021","volume":"147","author":"V Guarneri","year":"2021","unstructured":"Guarneri\u00a0V, Bassan\u00a0F, Zagonel\u00a0V et\u00a0al (2021) Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19\u00a0study. Eur J Cancer 147:120\u2013127. https:\/\/doi.org\/10.1016\/j.ejca.2021.01.021","journal-title":"Eur J Cancer"},{"key":"1853_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejca.2020.08.011","volume":"139","author":"KS Saini","year":"2020","unstructured":"Saini\u00a0KS, Tagliamento\u00a0M, Lambertini\u00a0M et\u00a0al (2020) Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52\u00a0studies. Eur J Cancer 139:43\u201350. https:\/\/doi.org\/10.1016\/j.ejca.2020.08.011","journal-title":"Eur J Cancer"},{"key":"1853_CR6","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1158\/2159-8290.CD-20-0422","volume":"10","author":"M Dai","year":"2020","unstructured":"Dai\u00a0M, Liu\u00a0D, Liu\u00a0M et al (2020) Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov 10:783\u2013791. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0422","journal-title":"Cancer Discov"},{"key":"1853_CR7","doi-asserted-by":"publisher","first-page":"e936","DOI":"10.1634\/theoncologist.2020-0213","volume":"25","author":"HO Al-Shamsi","year":"2020","unstructured":"Al-Shamsi\u00a0HO, Alhazzani\u00a0W, Alhuraiji\u00a0A et al (2020) A practical approach to the management of cancer patients during the novel Coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group. Oncologist 25:e936\u2013e945. https:\/\/doi.org\/10.1634\/theoncologist.2020-0213","journal-title":"Oncologist"},{"key":"1853_CR8","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1007\/s00066-020-01681-1","volume":"196","author":"C Matuschek","year":"2020","unstructured":"Matuschek\u00a0C, Fischer\u00a0JC, Combs\u00a0SE et al (2020) Measures of infection prevention and incidence of SARS-CoV\u20112 infections in cancer patients undergoing radiotherapy in Germany, Austria and Switzerland. Strahlenther Onkol 196:1068\u20131079. https:\/\/doi.org\/10.1007\/s00066-020-01681-1","journal-title":"Strahlenther Onkol"},{"key":"1853_CR9","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1158\/1078-0432.CCR-20-2224","volume":"26","author":"A Madariaga","year":"2020","unstructured":"Madariaga\u00a0A, McMullen\u00a0M, Sheikh\u00a0S et al (2020) COVID-19 testing in patients with cancer: does one size fit all? Clin Cancer Res 26:4737\u20134742. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2224","journal-title":"Clin Cancer Res"},{"key":"1853_CR10","unstructured":"European Society for Medical Oncology (ESMO) COVID-19 adapted recommendations slide sets\u2014General recommendations. https:\/\/www.esmo.org\/guidelines\/covid-19-adapted-recommendations-slide-sets. Accessed 27 May 2021"},{"key":"1853_CR11","doi-asserted-by":"publisher","first-page":"e044644","DOI":"10.1136\/bmjopen-2020-044644","volume":"11","author":"X Qiu","year":"2021","unstructured":"Qiu\u00a0X, Miller\u00a0JC, MacFadden\u00a0DR, Hanage\u00a0WP (2021) Evaluating the contributions of strategies to prevent SARS-CoV\u20112 transmission in the healthcare setting: a\u00a0modelling study. BMJ Open 11:e44644. https:\/\/doi.org\/10.1136\/bmjopen-2020-044644","journal-title":"BMJ Open"},{"key":"1853_CR12","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3332\/ecancer.2020.1100","volume":"14","author":"G Haradaa","year":"2020","unstructured":"Haradaa\u00a0G, Antonacio\u00a0FF, Gongora\u00a0AB et al (2020) SARS-CoV\u20112 testing for asymptomatic adult cancer patients before initiating systemic treatments: a\u00a0systematic review. ecancer 14:1100. https:\/\/doi.org\/10.3332\/ecancer.2020.1100","journal-title":"ecancer"},{"key":"1853_CR13","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1007\/s00066-020-01698-6","volume":"196","author":"D Akuamoa-Boateng","year":"2020","unstructured":"Akuamoa-Boateng\u00a0D, Wegen\u00a0S, Ferdinandus\u00a0J et al (2020) Managing patient flows in radiation oncology during the COVID-19 pandemic: reworking existing treatment designs to prevent infections at a\u00a0German hot spot area University Hospital. Strahlenther Onkol 196:1080\u20131085. https:\/\/doi.org\/10.1007\/s00066-020-01698-6","journal-title":"Strahlenther Onkol"},{"key":"1853_CR14","doi-asserted-by":"publisher","first-page":"100002","DOI":"10.1016\/j.lanepe.2020.100002","volume":"1","author":"JP Skittrall","year":"2021","unstructured":"Skittrall\u00a0JP, Fortune\u00a0MD, Jalal\u00a0H et al (2021) Diagnostic tool or screening programme? Asymptomatic testing for SARS-CoV\u20112 needs clear goals and protocols. Lancet Reg Health - Eur 1:100002. https:\/\/doi.org\/10.1016\/j.lanepe.2020.100002","journal-title":"Lancet Reg Health - Eur"},{"key":"1853_CR15","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S0140-6736(21)00370-6","volume":"397","author":"A Fontanet","year":"2021","unstructured":"Fontanet\u00a0A, Autran\u00a0B, Lina\u00a0B et al (2021) SARS-CoV\u20112 variants and ending the COVID-19 pandemic. Lancet 397:952\u2013954. https:\/\/doi.org\/10.1016\/S0140-6736(21)00370-6","journal-title":"Lancet"},{"key":"1853_CR16","doi-asserted-by":"publisher","first-page":"e2023121","DOI":"10.1001\/jamanetworkopen.2020.23121","volume":"3","author":"MA Shah","year":"2020","unstructured":"Shah\u00a0MA, Mayer\u00a0S, Emlen\u00a0F et al (2020) Clinical screening for COVID-19 in asymptomatic patients with cancer. JAMA Netw Open 3:e2023121. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.23121","journal-title":"JAMA Netw Open"},{"key":"1853_CR17","doi-asserted-by":"publisher","first-page":"652535","DOI":"10.3389\/fonc.2021.652535","volume":"11","author":"TB Johannesen","year":"2021","unstructured":"Johannesen\u00a0TB, Smeland\u00a0S, Aaserud\u00a0S et al (2021) COVID-19 in cancer patients, risk factors for disease and adverse outcome, a\u00a0population-based study from Norway. Front Oncol 11:652535. https:\/\/doi.org\/10.3389\/fonc.2021.652535","journal-title":"Front Oncol"},{"key":"1853_CR18","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3390\/curroncol28010032","volume":"28","author":"N Meti","year":"2021","unstructured":"Meti\u00a0N, Tahmasebi\u00a0H, Leahey\u00a0A et al (2021) SARS-CoV\u20112 testing for asymptomatic patients with cancer prior and during treatment: a single centre experience. Curr Oncol 28:278\u2013282. https:\/\/doi.org\/10.3390\/curroncol28010032","journal-title":"Curr Oncol"},{"key":"1853_CR19","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1200\/JCO.20.01442","volume":"38","author":"AS Berghoff","year":"2020","unstructured":"Berghoff\u00a0AS, Gansterer\u00a0M, Bathke\u00a0AC et al (2020) SARS-CoV\u20112 testing in patients with cancer treated at a\u00a0tertiary care hospital during the COVID-19 pandemic. J\u00a0Clin Oncol 38:3547\u20133554. https:\/\/doi.org\/10.1200\/JCO.20.01442","journal-title":"J Clin Oncol"},{"key":"1853_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13014-020-01609-0","volume":"15","author":"S Marschner","year":"2020","unstructured":"Marschner\u00a0S, Corradini\u00a0S, Rauch\u00a0J et al (2020) SARS-CoV\u20112 prevalence in an asymptomatic cancer cohort\u2014Results and consequences for clinical routine. Radiat Oncol 15:165. https:\/\/doi.org\/10.1186\/s13014-020-01609-0","journal-title":"Radiat Oncol"},{"key":"1853_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13014-021-01760-2","volume":"16","author":"RS Prabhu","year":"2021","unstructured":"Prabhu\u00a0RS, Dhakal\u00a0R, Hicks\u00a0AS et al (2021) Implementation, adherence, and results of systematic SARS-CoV\u20112 testing for asymptomatic patients treated at a\u00a0tertiary care regional radiation oncology network. Radiat Oncol 16:28. https:\/\/doi.org\/10.1186\/s13014-021-01760-2","journal-title":"Radiat Oncol"},{"key":"1853_CR22","doi-asserted-by":"publisher","first-page":"100704","DOI":"10.1016\/j.adro.2021.100704","volume":"6","author":"C Modi","year":"2021","unstructured":"Modi\u00a0C, Dragun\u00a0AE, Henson\u00a0CF et al (2021) A statewide multi-institutional study of asymptomatic pre-treatment testing of radiation therapy patients for SARS-CoV\u20112 in a\u00a0high-incidence region of the United States. Adv Radiat Oncol 6:100704. https:\/\/doi.org\/10.1016\/j.adro.2021.100704","journal-title":"Adv Radiat Oncol"},{"key":"1853_CR23","doi-asserted-by":"publisher","first-page":"e13774","DOI":"10.7759\/cureus.13774","volume":"13","author":"L Cavanna","year":"2021","unstructured":"Cavanna\u00a0L, Citterio\u00a0C, Di Nunzio\u00a0C et al (2021) Prevalence of COVID-19 infection in asymptomatic cancer patients in a\u00a0district with high prevalence of SARS-CoV\u20112 in Italy. Cureus 13:e13774. https:\/\/doi.org\/10.7759\/cureus.13774","journal-title":"Cureus"},{"key":"1853_CR24","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/cam4.3692","volume":"10","author":"H Liu","year":"2021","unstructured":"Liu\u00a0H, Yang\u00a0D, Chen\u00a0X et al (2021) The effect of anticancer treatment on cancer patients with COVID-19: a systematic review and meta-analysis. Cancer Med 10:1043\u20131056. https:\/\/doi.org\/10.1002\/cam4.3692","journal-title":"Cancer Med"},{"key":"1853_CR25","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","volume":"21","author":"MC Garassino","year":"2020","unstructured":"Garassino\u00a0MC, Whisenant\u00a0JG, Huang\u00a0L\u2011C et al (2020) COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol 21:914\u2013922. https:\/\/doi.org\/10.1016\/S1470-2045(20)30314-4","journal-title":"Lancet Oncol"},{"key":"1853_CR26","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","volume":"395","author":"LY Lee","year":"2020","unstructured":"Lee\u00a0LY, Cazier\u00a0J\u2011B, Angelis\u00a0V et al (2020) COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a\u00a0prospective cohort study. Lancet 395:1919\u20131926. https:\/\/doi.org\/10.1016\/S0140-6736(20)31173-9","journal-title":"Lancet"},{"key":"1853_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000883","author":"F Nichetti","year":"2020","unstructured":"Nichetti\u00a0F, Bini\u00a0M, Ambrosini\u00a0M et al (2020) COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: the COVINT study. ESMO Open. https:\/\/doi.org\/10.1136\/esmoopen-2020-000883","journal-title":"ESMO Open"},{"key":"1853_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2020.06.027","volume":"136","author":"V Angelis","year":"2020","unstructured":"Angelis\u00a0V, Tippu\u00a0Z, Joshi\u00a0K et al (2020) Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer. Eur J Cancer 136:99\u2013106. https:\/\/doi.org\/10.1016\/j.ejca.2020.06.027","journal-title":"Eur J Cancer"},{"key":"1853_CR29","doi-asserted-by":"publisher","first-page":"8020","DOI":"10.1002\/cam4.3435","volume":"9","author":"L Hempel","year":"2020","unstructured":"Hempel\u00a0L, Piehler\u00a0A, Pfaffl\u00a0MW et al (2020) SARS-CoV\u20112 infections in cancer outpatients-most infected patients are asymptomatic carriers without impact on chemotherapy. Cancer Med 9:8020\u20138028. https:\/\/doi.org\/10.1002\/cam4.3435","journal-title":"Cancer Med"},{"key":"1853_CR30","unstructured":"von Lilienfeld-Toal M, Giesen N, Greinix H et al (2021) Coronavirus-Infektion (COVID-19) bei Patient*innen mit Blut- und Krebserkrankungen. onkopedia leitlinien. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/coronavirus-infektion-covid-19-bei-patient-innen-mit-blut-und-krebserkrankungen\/@@guideline\/html\/index.html. Accessed 27 May 2021"},{"key":"1853_CR31","doi-asserted-by":"publisher","first-page":"e0242958","DOI":"10.1371\/journal.pone.0242958","volume":"15","author":"I Arevalo-Rodriguez","year":"2020","unstructured":"Arevalo-Rodriguez\u00a0I, Buitrago-Garcia\u00a0D, Simancas-Racines\u00a0D et al (2020) False-negative results of initial RT-PCR assays for COVID-19: a systematic review. PLoS ONE 15:e242958. https:\/\/doi.org\/10.1371\/journal.pone.0242958","journal-title":"PLoS ONE"},{"key":"1853_CR32","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMc2100362","volume":"384","author":"SS Abdool Karim","year":"2021","unstructured":"Abdool Karim\u00a0SS, de Oliveira\u00a0T (2021) New SARS-CoV\u20112 variants\u2014Clinical, public health, and vaccine implications. N\u00a0Engl J Med 384:1866\u20131868. https:\/\/doi.org\/10.1056\/NEJMc2100362","journal-title":"N Engl J Med"},{"key":"1853_CR33","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","volume":"22","author":"L Monin","year":"2021","unstructured":"Monin\u00a0L, Laing\u00a0AG, Mu\u00f1oz-Ruiz\u00a0M et al (2021) Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a\u00a0prospective observational study. Lancet Oncol 22:765\u2013778. https:\/\/doi.org\/10.1016\/S1470-2045(21)00213-8","journal-title":"Lancet Oncol"},{"key":"1853_CR34","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1056\/NEJMe2103931","volume":"384","author":"KM Neuzil","year":"2021","unstructured":"Neuzil\u00a0KM (2021) Interplay between emerging SARS-CoV\u20112 variants and pandemic control. N\u00a0Engl J Med 384:1952\u20131954. https:\/\/doi.org\/10.1056\/NEJMe2103931","journal-title":"N Engl J Med"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-021-01853-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-021-01853-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-021-01853-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T14:04:25Z","timestamp":1647957865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-021-01853-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1853"],"URL":"https:\/\/doi.org\/10.1007\/s00066-021-01853-7","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,7]]},"assertion":[{"value":"6 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.\u00a0C.\u00a0Arnold, J.\u00a0von der Gr\u00fcn, M.\u00a0C.\u00a0Brekner, J.\u00a0Licher, E.\u00a0Fokas, C.\u00a0R\u00f6del and M.\u00a0Fleischmann declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional (Ethics Committee of the Medical Faculty of Goethe University Frankfurt, Germany [vote number: UCT-24-2021]) and\/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}